Tags

Type your tag names separated by a space and hit enter

Avian and pandemic influenza: an overview.
Vaccine. 2007 Apr 20; 25(16):3057-61.V

Abstract

Influenza A/H5N1 (avian influenza) has now caused 258 human infections (as of November 13, 2006), with an approximate 50% mortality rate. Because the virus is novel in terms of antigenic type and causes infection and illness, and because humans have no pre-existing immunity, the conditions for a possible pandemic exist. Additionally, wild migratory birds appear to be spreading the virus across ever larger geographic areas, and newer clade 2 influenza A/H5N1 viruses have begun to emerge. The US Congressional Budget Office has formally modeled the likely consequences of pandemic influenza and estimates that up to 2 million of the US population might die, with up to 40% of all workers ill for as long as 3 or more weeks. This brief overview will review basic virologic, immunologic and epidemiologic information relevant to understanding and preparing for this threat. In particular, the role of avian influenza vaccines will be reviewed.

Authors+Show Affiliations

Mayo Vaccine Research Group, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. poland.gregory@mayo.eduNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Review

Language

eng

PubMed ID

17289227

Citation

Poland, Gregory A., et al. "Avian and Pandemic Influenza: an Overview." Vaccine, vol. 25, no. 16, 2007, pp. 3057-61.
Poland GA, Jacobson RM, Targonski PV. Avian and pandemic influenza: an overview. Vaccine. 2007;25(16):3057-61.
Poland, G. A., Jacobson, R. M., & Targonski, P. V. (2007). Avian and pandemic influenza: an overview. Vaccine, 25(16), 3057-61.
Poland GA, Jacobson RM, Targonski PV. Avian and Pandemic Influenza: an Overview. Vaccine. 2007 Apr 20;25(16):3057-61. PubMed PMID: 17289227.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Avian and pandemic influenza: an overview. AU - Poland,Gregory A, AU - Jacobson,Robert M, AU - Targonski,Paul V, Y1 - 2007/01/18/ PY - 2007/2/10/pubmed PY - 2007/7/11/medline PY - 2007/2/10/entrez SP - 3057 EP - 61 JF - Vaccine JO - Vaccine VL - 25 IS - 16 N2 - Influenza A/H5N1 (avian influenza) has now caused 258 human infections (as of November 13, 2006), with an approximate 50% mortality rate. Because the virus is novel in terms of antigenic type and causes infection and illness, and because humans have no pre-existing immunity, the conditions for a possible pandemic exist. Additionally, wild migratory birds appear to be spreading the virus across ever larger geographic areas, and newer clade 2 influenza A/H5N1 viruses have begun to emerge. The US Congressional Budget Office has formally modeled the likely consequences of pandemic influenza and estimates that up to 2 million of the US population might die, with up to 40% of all workers ill for as long as 3 or more weeks. This brief overview will review basic virologic, immunologic and epidemiologic information relevant to understanding and preparing for this threat. In particular, the role of avian influenza vaccines will be reviewed. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/17289227/Avian_and_pandemic_influenza:_an_overview_ DB - PRIME DP - Unbound Medicine ER -